Continuing Education Activity

Salmeterol is a long-acting beta-2 adrenergic agonist used in the long-term management of asthma and chronic obstructive pulmonary disease (COPD). Appropriate use of salmeterol requires an understanding of its therapeutic role, safety profile, dosing considerations, and place within current guideline-directed treatment strategies. This activity reviews the pharmacologic properties, mechanism of action, approved indications, administration, adverse effects, contraindications, monitoring requirements, and toxicity associated with salmeterol therapy. Emphasis is placed on the integration of salmeterol into contemporary asthma and COPD management, including its use in inhaled corticosteroid-containing regimens, recognition of potential adverse effects, and prevention of medication-related complications. Participants will enhance their understanding of evidence-based salmeterol use, appropriate patient monitoring, and risk mitigation strategies while developing skills to support inhaler optimization, treatment adherence, and coordinated interprofessional care to improve patient outcomes.

Objectives:

• Identify patients with asthma or chronic obstructive pulmonary disease who are appropriate candidates for salmeterol therapy based on current guideline recommendations.
• Select appropriate salmeterol-containing formulations and dosing regimens based on patient age, disease severity, comorbidities, and treatment goals.
• Assess signs and symptoms of salmeterol toxicity, overdose, and medication-related adverse effects and implement evidence-based management strategies to reduce the risk of complications.
• Collaborate with physicians, pharmacists, nurses, respiratory therapists, and other healthcare professionals to develop individualized management plans that improve respiratory outcomes and reduce exacerbation risk.

Access free multiple choice questions on this topic.

Indications

Salmeterol is a highly selective long-acting beta-2 adrenergic agonist (LABA) indicated for the treatment of asthma, maintenance therapy for airflow obstruction in chronic obstructive pulmonary disease (COPD), and prevention of exercise-induced bronchospasm (EIB).[1][2][3][4] In asthma management, salmeterol is used in combination with inhaled corticosteroids (ICSs).[5] Current asthma guidelines recommend ICS-formoterol–based regimens as the preferred controller and reliever therapy, whereas salmeterol-containing ICS-LABA combinations are considered alternative maintenance options, used with a separate short-acting beta-agonist for symptom relief.[6]

Because salmeterol has a slower onset of action than formoterol, it is not suitable for single-inhaler maintenance-and-reliever therapy. Salmeterol should not be used as monotherapy for asthma because LABA monotherapy has been associated with an increased risk of serious asthma-related adverse outcomes.[7]

In COPD, salmeterol has historically been used as a maintenance bronchodilator therapy.[8] Current guidelines generally recommend LABA plus long-acting muscarinic antagonist (LAMA) dual bronchodilation as initial maintenance therapy for symptomatic patients, with LABA monotherapy reserved for selected situations in which dual therapy is not appropriate or available.[9] Salmeterol has been shown to improve lung function, including forced expiratory volume in 1 second, in patients with asthma and COPD.[10]

Following the approval of salmeterol xinafoate in 1994, the US Food and Drug Administration (FDA) approved fluticasone propionate/salmeterol (FP/SAL) as a fixed-dose combination therapy for the treatment of asthma and COPD. The fluticasone/salmeterol combination provides sustained bronchodilation, prevention of exacerbations, improved lung function, and reduced use of rescue medication.[11] As understanding of COPD management continues to evolve, the role of ICS-containing regimens has become more refined. When ICS therapy is clinically indicated in COPD, particularly in patients with a blood eosinophil count greater than 300 cells/µL and a history of exacerbations, triple therapy with a LABA, LAMA, and ICS is now preferred over dual LABA/ICS therapy, as it has demonstrated superior outcomes in exacerbation prevention, lung function, and quality of life.[9][12]

Salmeterol is approximately 10 times more potent than albuterol on a weight-for-weight basis and provides a prolonged bronchodilator effect lasting approximately 12 hours.[13][14] Additionally, salmeterol has a much higher beta-2/beta-1 selectivity ratio than albuterol, with ratios of 50,000:1 and 650:1, respectively.[14]

A head-to-head study comparing salmeterol and salbutamol (albuterol) demonstrated that inhaled salmeterol was clinically superior, providing sustained bronchodilation and better prevention of asthma symptoms than salbutamol. Outcomes favoring salmeterol included pulmonary function, peak expiratory flow, the need for supplemental bronchodilators, the frequency of nocturnal awakenings, and the occurrence and severity of daily asthma symptoms.[14] Salmeterol is used as a maintenance therapy in asthma and COPD and should never be used to treat acute bronchospasm.[6]

Mechanism of Action

Salmeterol belongs to the group of drugs known as beta-2 agonists. Beta-2 agonists act on G protein–coupled receptors linked to the stimulatory G protein (Gs).[15] The Gs protein stimulates adenylyl cyclase, which converts adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Subsequently, cAMP activates protein kinase A, inhibiting myosin light chain kinase (present in airway smooth muscle). This cascade results in the relaxation of bronchiolar smooth muscle, bronchodilation, and increased airflow through the bronchioles.[15][16][17]

In human lungs, salmeterol also inhibits the release of mast cell mediators, including histamine, leukotrienes, and prostaglandins. Although these effects may contribute modestly to reduced airway inflammation, bronchodilation remains the primary therapeutic action of salmeterol.

Salmeterol’s molecular structure contributes to its prolonged duration of action. Its elongated lipophilic side chain facilitates repeated activation of the beta-2 receptor by binding to an "exosite" adjacent to the receptor-binding site. This mechanism allows the active portion of the molecule to repeatedly interact with the receptor over an extended period.[18] Due to this unique structure, a single inhaled dose of salmeterol produces bronchodilation for approximately 12 hours, compared with 4 to 6 hours for salbutamol (albuterol). Clinical studies have demonstrated that twice-daily salmeterol provides sustained bronchodilation and improved asthma symptom control compared with regularly scheduled or as-needed albuterol therapy.[14]

Pharmacokinetics

Salmeterol is metabolized predominantly by CYP3A4, a cytochrome P450 isoenzyme responsible for aliphatic oxidation of the salmeterol molecule. Salmeterol undergoes extensive hepatic metabolism to alpha-hydroxy-salmeterol and is subsequently eliminated primarily in the feces, with lesser urinary excretion. Approximately 57.4% is eliminated in feces and 23% in urine.[19][20]

At recommended therapeutic doses, systemic concentrations of salmeterol are generally low or undetectable. Clinically significant drug interactions related to CYP3A4 metabolism are unlikely at standard inhaled doses.[20] However, caution is advised in patients with severe hepatic impairment because reduced clearance may increase systemic exposure.

Concomitant use of salmeterol with potent CYP3A4 inhibitors is generally not recommended because increased systemic exposure may raise the risk of cardiovascular adverse effects. In combination with ICS/LABA formulations, CYP3A4 inhibition may also increase systemic corticosteroid exposure. Examples of potent CYP3A4 inhibitors include ritonavir, atazanavir, indinavir, nelfinavir, saquinavir, itraconazole, ketoconazole, nefazodone, clarithromycin, and telithromycin.[21]

Administration

Available Dosage Forms and Strengths

Salmeterol is available as an inhalation powder and as part of fixed-dose ICS/LABA combinations. The most commonly used formulations contain fluticasone propionate and salmeterol. Because salmeterol should not be used as monotherapy in asthma, fixed-dose ICS/LABA combinations help ensure concomitant anti-inflammatory therapy.[7][11]

Salmeterol is currently available as an oral inhalation powder and an oral inhalation aerosol.

• The inhalation powder is available as a single-agent dry powder inhaler containing 50 mcg of salmeterol per actuation.
• The inhalation powder is also available in combination with fluticasone propionate at strengths of 100, 250, and 500 mcg, each combined with a fixed salmeterol dose of 50 mcg per actuation.
• An aerosol metered-dose inhaler (MDI) is available with fluticasone propionate doses of 45, 115, and 230 mcg, each combined with a fixed salmeterol dose of 21 mcg per actuation. The MDI uses a hydrofluoroalkane propellant.

A randomized non-inferiority trial demonstrated comparable asthma control and morning peak expiratory flow across different fluticasone/salmeterol formulations, suggesting similar efficacy regardless of the delivery mechanism.[22] 

Dosage for asthma: For the treatment of asthma in patients aged 12 and older, the recommended dosage is 1 inhalation of fluticasone/salmeterol 100/50, 250/50, or 500/50 mcg inhalation powder twice daily.[1] The starting dosage is determined by asthma severity. Alternatively, fluticasone/salmeterol inhalation aerosol 45/21, 115/21, or 230/21 mcg is administered as 2 inhalations twice daily. After inhalation, patients should rinse their mouths with water and spit out the contents without swallowing to reduce the risk of oral candidiasis.[23]

Chronic obstructive pulmonary disease: For maintenance treatment of bronchospasm associated with COPD, the recommended dosage is 1 inhalation of 50 mcg twice daily in combination with ICS, administered approximately 12 hours apart.[2]

Exercise-induced bronchospasm: For the prevention of EIB, single-agent salmeterol inhalation powder may be clinically indicated for patients without persistent asthma. In these patients, 1 inhalation of 50 mcg administered 20 to 30 minutes before exercise has been shown to provide protection against EIB. The bronchodilatory effects generally last approximately 9 hours in adults and 12 hours in children aged 4 to 11 years.[24][3] In patients with persistent asthma, salmeterol monotherapy is contraindicated.[3]

Specific Patient Populations

Hepatic impairment: No dosage recommendations are available for patients with hepatic impairment. Because salmeterol is extensively metabolized in the liver, plasma concentrations may increase in patients with significant hepatic dysfunction. Cautious use with appropriate clinical monitoring is advised for these patients.

Renal impairment: Manufacturer labeling does not provide specific dosing recommendations for patients with renal impairment. Because only a small proportion of salmeterol is eliminated renally, clinically significant accumulation is considered unlikely.

Pregnancy considerations: According to the 2024 Global Initiative for Asthma (GINA) guidelines, use of inhaled beta-2 agonists during pregnancy has not been associated with an increased risk of fetal malformations. Poorly controlled asthma during pregnancy is associated with adverse maternal and fetal outcomes, and in many cases, the risks associated with uncontrolled asthma or asthma exacerbations often exceed those associated with asthma medications. Effective maternal asthma management has been shown to improve pregnancy outcomes and decrease the likelihood of certain complications.[25][26]

Salmeterol is considered one of the preferred LABAs for asthma management during pregnancy because of the available clinical safety experience. According to GINA recommendations, reducing maintenance asthma therapy during pregnancy is generally discouraged. Asthma control should be reassessed every 4 to 6 weeks throughout pregnancy.[25]

Breastfeeding considerations: Whether salmeterol is excreted into human breast milk is unknown. According to manufacturer recommendations, decisions regarding breastfeeding during salmeterol therapy should consider the potential risks and benefits to the infant as well as the therapeutic benefits to the mother.

Pediatric considerations: For the treatment of asthma in children aged 4 to 11, the recommended dosage is 1 inhalation of fluticasone/salmeterol 100/50 mcg twice daily.[1] Safety and efficacy have not been established in children younger than 4 years.

Adverse Effects

The most common adverse reactions associated with salmeterol are pain and headache. Other adverse reactions reported at an incidence of 3% or greater among patients with asthma include upper respiratory infection, oral candidiasis, pharyngitis, bronchitis, dysphonia, cough, and nausea. In patients with COPD, combination therapy containing salmeterol and ICSs, particularly fluticasone, has been associated with adverse effects including pneumonia, oral candidiasis, dysphonia, throat irritation, headache, and musculoskeletal pain.[27]

Immediate hypersensitivity reactions may occur. Patients may present with urticaria, rash, angioedema, bronchospasm, headache, tremor, or anaphylaxis. 

More severe adverse effects associated with salmeterol overdose result from excessive beta-adrenergic stimulation caused by systemic absorption. Although salmeterol is a highly selective beta-2 agonist, it exhibits some beta-1 activity and may cause cardiovascular effects. These manifestations include angina, tachycardia, hypertension, hypotension, arrhythmias, palpitations, and fatigue. Additional manifestations may include tremor, hypokalemia, and hyperglycemia, which are consistent with excessive systemic beta-adrenergic stimulation.[28]

The cardiovascular risk profile of LABAs in COPD is complex. Although earlier studies raised concerns regarding potential cardiovascular events, more recent evidence suggests that LABA-containing regimens, particularly triple therapy, may be associated with reduced cardiovascular morbidity and exacerbation frequency compared with dual bronchodilation alone.[29] These potential benefits may be related, in part, to improved exacerbation control and reduced systemic inflammatory burden. Clinicians are encouraged to proactively screen for and manage cardiovascular comorbidities in this patient population.[9] Paradoxical bronchospasm, laryngeal spasm, and throat swelling may occur. Paradoxical bronchospasm has been reported more commonly in patients using MDIs.[30]

Contraindications

Salmeterol is contraindicated in patients with hypersensitivity to the drug or any of its components, including lactose or milk protein, as well as in those with a history of adverse reactions to salmeterol.[31]

Box Warnings

The FDA has issued a boxed warning regarding the increased incidence of asthma-related deaths associated with salmeterol use in patients with asthma. Current prescribing recommendations emphasize that salmeterol should not be used as monotherapy for asthma and should be administered in combination with an ICS. Clinicians should use salmeterol as adjunctive therapy only in patients whose asthma is not adequately controlled with other therapies, such as low- to medium-dose inhaled steroids, or those with severe asthma requiring 2 maintenance therapies.

Warnings and Precautions

Salmeterol should not be used for status asthmaticus or other acute asthma episodes. Salmeterol should not be used in combination with other LABAs. Studies have demonstrated an increased risk of asthma-related death in patients receiving salmeterol monotherapy compared with placebo; this risk appears to be reduced when salmeterol is used in combination with an ICS.[32] Earlier studies suggested a higher observed risk among African American patients; however, subsequent analyses indicate that inadequate ICS use and asthma severity may have contributed to this finding. Additionally, the concurrent use of an ICS-formoterol reliever inhaler in patients already prescribed a salmeterol-containing maintenance inhaler should be avoided because it constitutes dual LABA administration and carries a risk of bronchodilator overdose with potential cardiovascular consequences.[6]

Although not contraindicated, salmeterol should be used with caution in patients with cardiovascular disease, convulsive disorders, hepatic impairment, diabetes mellitus, hyperthyroidism or thyrotoxicosis, or concomitant use of CYP3A inhibitors because these factors may increase toxicity and prolong the patient’s QT interval. Salmeterol should also be used with caution in patients with hypokalemia because of the risk of transient hypokalemia.

Monitoring

Monitoring parameters for salmeterol include heart rate, blood pressure, pulmonary function, forced expiratory volume in 1 second, peak expiratory flow, the frequency of nocturnal awakenings, central nervous system stimulation, and the occurrence and severity of asthma symptoms.[33]

Please refer to the Contraindications section for conditions that may warrant periodic monitoring of blood glucose, potassium, thyroid function, hepatic function, and the QT interval, particularly in patients receiving concomitant CYP3A4 inhibitors. Patients with hepatic impairment require close monitoring because decreased hepatic function may lead to salmeterol accumulation in the plasma.[21]

Toxicity

Signs and Symptoms of Overdose

Reports describe sympathomimetic syndrome with hyperlactatemia and metabolic acidosis following the intentional inhalation of salmeterol in a suicide attempt. Patients who overdose commonly present with palpitations, chest pain, hypophosphatemia, hypokalemia, lactic acidosis, ST-segment depression, and sinus tachycardia. Patients may also present with angina, hypotension, hypertension, dizziness, nausea, fatigue, malaise, insomnia, and muscle cramps. Salmeterol overdose can lead to QT interval prolongation, resulting in ventricular arrhythmias.[28]

Management of Overdose

Management of symptomatic salmeterol overdose is primarily supportive and includes intravenous fluids, careful potassium supplementation, continuous cardiac monitoring, and correction of electrolyte abnormalities. A cardioselective beta-blocker may be considered in selected patients with significant cardiovascular toxicity; however, caution is warranted because beta-blockers may precipitate bronchospasm in susceptible individuals.

Enhancing Healthcare Team Outcomes

Because most patients with COPD and many patients with moderate-to-severe asthma require long-term treatment with LABAs, a patient-centered approach involving multidisciplinary coordination is essential. In primary care settings, integration of respiratory therapists into the healthcare team has been associated with improved quality of asthma care. Specialized care has been associated with improved patient outcomes, including reduced reliance on rescue inhalers and improved symptom control. Additionally, facilities with a designated respiratory care specialist have demonstrated improved inhaler technique and increased spirometry utilization. Current guidelines recommend that all patients with asthma receive a personalized written asthma action plan, a responsibility shared across the interprofessional team, including prescribers, pharmacists, and nurses.[6] In COPD management, the blood eosinophil count should be routinely used to guide ICS prescribing decisions. Clinical pharmacists can support eosinophil-guided treatment selection and reassessment during follow-up encounters.[9]

Pharmacists assist in verifying medication dosing and reinforcing proper inhalation technique. Nurses can educate patients, monitor care, and assess therapeutic effectiveness. In geriatric populations, long-term care facilities may play an important role in promoting medication adherence and coordinating outpatient follow-up care.[34] An interprofessional team-based approach involving physicians, respiratory therapists, respiratory care specialists, specialty-trained nurses, pharmacists, and patients can improve symptom control, reduce acute exacerbations, and enhance quality of life.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

D'Alonzo GE, Tolep KA. Salmeterol in the treatment of chronic asthma. Am Fam Physician. 1997 Aug;56(2):558-62. [PubMed: 9262535]

2.

Yawn BP, Raphiou I, Hurley JS, Dalal AA. The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2010 Jun 03;5:165-78. [PMC free article: PMC2898089] [PubMed: 20631816]

3.

Bronsky EA, Pearlman DS, Pobiner BF, Scott C, Wang Y, Stahl E. Prevention of exercise-induced bronchospasm in pediatric asthma patients: A comparison of two salmeterol powder delivery devices. Pediatrics. 1999 Sep;104(3 Pt 1):501-6. [PubMed: 10469776]

4.

Green CP, Price JF. Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Arch Dis Child. 1992 Aug;67(8):1014-7. [PMC free article: PMC1793593] [PubMed: 1355645]

5.

Kavuru M, Melamed J, Gross G, Laforce C, House K, Prillaman B, Baitinger L, Woodring A, Shah T. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1108-16. [PubMed: 10856143]

6.

Dubin S, Patak P, Jung D. Update on Asthma Management Guidelines. Mo Med. 2024 Sep-Oct;121(5):364-367. [PMC free article: PMC11482852] [PubMed: 39421468]

7.

Lommatzsch M, Lindner Y, Edner A, Bratke K, Kuepper M, Virchow JC. Adverse effects of salmeterol in asthma: a neuronal perspective. Thorax. 2009 Sep;64(9):763-9. [PMC free article: PMC2730557] [PubMed: 19237390]

8.

Santus P, Radovanovic D, Paggiaro P, Papi A, Sanduzzi A, Scichilone N, Braido F. Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol. Eur J Intern Med. 2015 Jul;26(6):379-84. [PubMed: 26049917]

9.

Venkatesan P. GOLD COPD report: 2025 update. Lancet Respir Med. 2025 Jan;13(1):e7-e8. [PubMed: 39647487]

10.

Grove A, Lipworth BJ, Reid P, Smith RP, Ramage L, Ingram CG, Jenkins RJ, Winter JH, Dhillon DP. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax. 1996 Jul;51(7):689-93. [PMC free article: PMC472490] [PubMed: 8882074]

11.

Calzetta L, Ritondo BL, Matera MG, Cazzola M, Rogliani P. Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. Expert Rev Respir Med. 2020 Jun;14(6):621-635. [PubMed: 32168461]

12.

Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes de Oca M, Mortimer K, Papi A, Pavord I, Roche N, Salvi S, Sin DD, Singh D, Stockley R, López Varela MV, Wedzicha JA, Vogelmeier CF. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023 Apr;61(4) [PMC free article: PMC10066569] [PubMed: 36858443]

13.

Smyth ET, Pavord ID, Wong CS, Wisniewski AF, Williams J, Tattersfield AE. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ. 1993 Feb 27;306(6877):543-5. [PMC free article: PMC1677185] [PubMed: 8096416]

14.

Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, Dockhorn RJ, Grossman J, Liddle RF, Yancey SW. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992 Nov 12;327(20):1420-5. [PubMed: 1357554]

15.

Billington CK, Penn RB, Hall IP. β₂ Agonists. Handb Exp Pharmacol. 2017;237:23-40. [PMC free article: PMC5480238] [PubMed: 27878470]

16.

Barisione G, Baroffio M, Crimi E, Brusasco V. Beta-Adrenergic Agonists. Pharmaceuticals (Basel). 2010 Mar 30;3(4):1016-1044. [PMC free article: PMC4034018] [PubMed: 27713285]

17.

Song N, Fang Y, Sun X, Jiang Q, Song C, Chen M, Ding J, Lu M, Hu G. Salmeterol, agonist of β2-aderenergic receptor, prevents systemic inflammation via inhibiting NLRP3 inflammasome. Biochem Pharmacol. 2018 Apr;150:245-255. [PubMed: 29447945]

18.

Johnson M, Butchers PR, Coleman RA, Nials AT, Strong P, Sumner MJ, Vardey CJ, Whelan CJ. The pharmacology of salmeterol. Life Sci. 1993;52(26):2131-43. [PubMed: 8099695]

19.

Manchee GR, Eddershaw PJ, Ranshaw LE, Herriott D, Park GR, Bayliss MK, Tarbit MH. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A. Drug Metab Dispos. 1996 May;24(5):555-9. [PubMed: 8723736]

20.

Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet. 2002;41(1):19-30. [PubMed: 11825095]

21.

Teply R, Campbell J, Hilleman D. Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone. J Asthma Allergy. 2010 Mar 11;3:1-8. [PMC free article: PMC3047914] [PubMed: 21437034]

22.

Kupczyk M, Majak P, Kuna P, Asankowicz-Bargiel B, Barańska E, Dobek R, Garbicz S, Jerzyńska J, Latos A, Machowiak W, Majorek-Olechowska B, Olech-Cudzik A, Poziomkowska-Gęsicka I, Rulewicz-Warniełło M, Świderska A, Tarnowski M, Kopyto P. A new formulation of fluticasone propionate/salmeterol in a metered-dose inhaler (MDI HFA) allows for the reduction of a daily dose of corticosteroid and provides optimal asthma control - A randomized, multi-center, non-inferiority, phase IV clinical study. Respir Med. 2021 Jan;176:106274. [PubMed: 33276251]

23.

Godara N, Godara R, Khullar M. Impact of inhalation therapy on oral health. Lung India. 2011 Oct;28(4):272-5. [PMC free article: PMC3213714] [PubMed: 22084541]

24.

Kemp JP, Dockhorn RJ, Busse WW, Bleecker ER, Van As A. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1612-5. [PubMed: 7952623]

25.

Middleton PG, Gade EJ, Aguilera C, MacKillop L, Button BM, Coleman C, Johnson B, Albrechtsen C, Edenborough F, Rigau D, Gibson PG, Backer V. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020 Feb;55(2) [PubMed: 31699837]

26.

Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, Fleming LJ, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Mortimer K, Pitrez PM, Sheikh A, Yorgancioglu AA, Boulet LP. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. J Allergy Clin Immunol Pract. 2022 Jan;10(1S):S1-S18. [PubMed: 34718211]

27.

Spencer CM, Jarvis B. Salmeterol/fluticasone propionate combination. Drugs. 1999 Jun;57(6):933-40; discussion 941-3. [PubMed: 10400406]

28.

Manara A, Hantson P, Vanpee D, Thys F. Lactic acidosis following intentional overdose by inhalation of salmeterol and fluticasone. CJEM. 2012 Nov;14(6):378-81. [PubMed: 23131487]

29.

Wu J, Ye Y, Li C, Zhou W, Chang R. Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol. 2019 Sep;74(3):255-265. [PubMed: 31306366]

30.

Wilkinson JR, Roberts JA, Bradding P, Holgate ST, Howarth PH. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ. 1992 Oct 17;305(6859):931-2. [PMC free article: PMC1883565] [PubMed: 1360855]

31.

Robles J, Motheral L. Hypersensitivity reaction after inhalation of a lactose-containing dry powder inhaler. J Pediatr Pharmacol Ther. 2014 Jul;19(3):206-11. [PMC free article: PMC4187530] [PubMed: 25309152]

32.

Rider NL, Craig TJ. A safety review of long-acting beta2-agonists in patients with asthma. J Am Osteopath Assoc. 2006 Sep;106(9):562-7. [PubMed: 17079526]

33.

Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, Matera MG. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest. 1998 Aug;114(2):411-5. [PubMed: 9726723]

34.

Hart MK, Millard MW. Approaches to chronic disease management for asthma and chronic obstructive pulmonary disease: strategies through the continuum of care. Proc (Bayl Univ Med Cent). 2010 Jul;23(3):223-9. [PMC free article: PMC2900972] [PubMed: 20671816]

Disclosure: Shraddha Narechania declares no relevant financial relationships with ineligible companies.

Disclosure: Sarvesh Sharma declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.